{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:12:48Z","timestamp":1790968368395,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,2,4]],"date-time":"2010-02-04T00:00:00Z","timestamp":1265241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,2,4]],"date-time":"2010-02-04T00:00:00Z","timestamp":1265241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1038\/leu.2009.299","type":"journal-article","created":{"date-parts":[[2010,2,4]],"date-time":"2010-02-04T10:45:30Z","timestamp":1265280330000},"page":"771-778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors"],"prefix":"10.1038","volume":"24","author":[{"given":"D K","family":"Hiwase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V A","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Zrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Frede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Guthridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A F","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R J","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L B","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J V","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,4]]},"reference":[{"key":"BFleu2009299_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD . Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290\u2013293.","journal-title":"Nature"},{"key":"BFleu2009299_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 1990; 247: 824\u2013830.","journal-title":"Science"},{"key":"BFleu2009299_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079\u20131082.","journal-title":"Science"},{"key":"BFleu2009299_CR4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2032Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2009299_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58\u201360.","journal-title":"Blood"},{"key":"BFleu2009299_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/sj.leu.2404893","volume":"22","author":"M Bocchia","year":"2008","unstructured":"Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E, Calabrese S, Amabile M et al. CD34+\/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia 2008; 22: 426\u2013428.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR7","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532\u20134539.","journal-title":"Blood"},{"key":"BFleu2009299_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319\u2013325.","journal-title":"Blood"},{"key":"BFleu2009299_CR9","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+CML cells. Blood 2007; 109: 4016\u20134019.","journal-title":"Blood"},{"key":"BFleu2009299_CR10","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","volume":"19","author":"MS Holtz","year":"2005","unstructured":"Holtz MS, Forman SJ, Bhatia R . Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005; 19: 1034\u20131041.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR11","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/sj.leu.2403785","volume":"19","author":"HG Jorgensen","year":"2005","unstructured":"Jorgensen HG, Allan EK, Graham SM, Godden JL, Richmond L, Elliott MA et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 2005; 19: 1184\u20131191.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR12","doi-asserted-by":"publisher","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","volume":"68","author":"H Konig","year":"2008","unstructured":"Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R . Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008; 68: 9624\u20139633.","journal-title":"Cancer Res"},{"key":"BFleu2009299_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","volume":"14","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008; 14: 485\u2013493.","journal-title":"Cancer Cell"},{"key":"BFleu2009299_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/sj.leu.2405086","volume":"22","author":"H Konig","year":"2008","unstructured":"Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748\u2013755.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","volume":"91","author":"P le Coutre","year":"1999","unstructured":"le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R et al. In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91: 163\u2013168.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2009299_CR16","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935\u2013942.","journal-title":"J Clin Oncol"},{"key":"BFleu2009299_CR17","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/leu.2009.88","volume":"23","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX . Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009; 23: 1537\u20131544.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR18","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/leu.2009.156","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, Muller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009; 23: 1628\u20131633.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR19","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH et al. Intermittent target inhibition with dasatinib 100\u2009mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204\u20133212.","journal-title":"J Clin Oncol"},{"key":"BFleu2009299_CR20","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","volume":"114","author":"JL Snead","year":"2009","unstructured":"Snead JL, O\u2019Hare T, Adrian LT, Eide CA, Lange T, Druker BJ et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009; 114: 3459\u20133463.","journal-title":"Blood"},{"key":"BFleu2009299_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/leu.2009.45","volume":"23","author":"DK Hiwase","year":"2009","unstructured":"Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP . Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells. Leukemia 2009; 23: 1205\u20131206.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR22","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","volume":"14","author":"DK Hiwase","year":"2008","unstructured":"Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008; 14: 3881\u20133888.","journal-title":"Clin Cancer Res"},{"key":"BFleu2009299_CR23","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","volume":"106","author":"D White","year":"2005","unstructured":"White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520\u20132526.","journal-title":"Blood"},{"key":"BFleu2009299_CR24","volume-title":"Clinical Pharmacology Review: Spycel, Dasatinib","author":"J Bullock","year":"2006","unstructured":"Bullock J, Noory C, Men A, Ramchandani RLK . Clinical Pharmacology Review: Spycel, Dasatinib, Application number 21-986. US Food and Drug Administration, Center for Drug Evaluation and Research 2006, http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/briefing\/2006-4220-B1-01BristolMyersSquibb-Background.pdf."},{"key":"BFleu2009299_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926\u2013935.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/leu.2008.246","volume":"23","author":"N Misaghian","year":"2009","unstructured":"Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 25\u201342.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR27","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","volume":"108","author":"NE Jordanides","year":"2006","unstructured":"Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC . Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006; 108: 1370\u20131373.","journal-title":"Blood"},{"key":"BFleu2009299_CR28","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","volume":"19","author":"A Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Muller-Brusselbach S et al. Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development. Leukemia 2005; 19: 1774\u20131782.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR29","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation. Blood 2007; 109: 2147\u20132155.","journal-title":"Blood"},{"key":"BFleu2009299_CR30","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","volume":"103","author":"S Chu","year":"2004","unstructured":"Chu S, Holtz M, Gupta M, Bhatia R . BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004; 103: 3167\u20133174.","journal-title":"Blood"},{"key":"BFleu2009299_CR31","doi-asserted-by":"publisher","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","volume":"96","author":"X Jiang","year":"1999","unstructured":"Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C . Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A 1999; 96: 12804\u201312809.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFleu2009299_CR32","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V84.6.1760.1760","volume":"84","author":"SS Tian","year":"1994","unstructured":"Tian SS, Lamb P, Seidel HM, Stein RB, Rosen J . Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor. Blood 1994; 84: 1760\u20131764.","journal-title":"Blood"},{"key":"BFleu2009299_CR33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood.V83.4.949.bloodjournal834949","volume":"83","author":"A Bashey","year":"1994","unstructured":"Bashey A, Healy L, Marshall CJ . Proliferative but not nonproliferative responses to granulocyte colony-stimulating factor are associated with rapid activation of the p21ras\/MAP kinase signalling pathway. Blood 1994; 83: 949\u2013957.","journal-title":"Blood"},{"key":"BFleu2009299_CR34","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood.V95.5.1656.005k29_1656_1662","volume":"95","author":"F Dong","year":"2000","unstructured":"Dong F, Larner AC . Activation of Akt kinase by granulocyte colony-stimulating factor (G-CSF): evidence for the role of a tyrosine kinase activity distinct from the Janus kinases. Blood 2000; 95: 1656\u20131662.","journal-title":"Blood"},{"key":"BFleu2009299_CR35","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/leu.2008.364","volume":"23","author":"F Belloc","year":"2009","unstructured":"Belloc F, Airiau K, Jeanneteau M, Garcia M, Guerin E, Lippert E et al. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia 2009; 23: 679\u2013685.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/sj.leu.2403335","volume":"18","author":"Y Chalandon","year":"2004","unstructured":"Chalandon Y, Jiang X, Loutet S, Eaves AC, Eaves CJ . Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL. Leukemia 2004; 18: 1006\u20131012.","journal-title":"Leukemia"},{"key":"BFleu2009299_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/leu.2008.3","volume":"22","author":"J Liu","year":"2008","unstructured":"Liu J, Joha S, Idziorek T, Corm S, Hetuin D, Philippe N et al. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia 2008; 22: 791\u2013799.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2009299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2009299","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2009299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:03:57Z","timestamp":1648728237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2009299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["BFleu2009299"],"URL":"https:\/\/doi.org\/10.1038\/leu.2009.299","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,4]]},"assertion":[{"value":"10 September 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Devendra K Hiwase, Jason A Powell, Verity A Saunders, Stephanie A Zrim, Amity K Frede, Mark A Guthridge, Richard J D\u2019andrea, Luen Bik To, Junia V Melo and Sharad Kumar have no conflict of interest. Timothy Hughes and Deborah L White receive honoraria and research grants from Novartis and Bristol-Myers Squibb. Angel F Lopez receives honoraria and research grants from CSL.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}